Healthcare / BiotechnologyStockholm
$3.26
-0.21 (-6.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $20.4M · quality 38.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$344M
P/E
3.5x
↓EV/EBITDA
1.9x
↓ROE
77.0%
↑Gross Margin
92.2%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+47.7%
FCF CAGR
—
FCF margin
49.9%
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $167.2M · net income $91.7M · FCF $83.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $167.2M | $167.2M | $65.6M | $50.5M | — | $35.1M |
| Net Income | $91.7M | $91.7M | $-18.3M | $-438000.00 | — | $-25.1M |
| EBITDA | $93.2M | $93.2M | $-17.3M | $-2.1M | — | $-24.2M |
| EPS | 0.98 | 0.98 | -0.26 | -0.01 | — | -0.71 |
| Gross Margin | 92.2% | 92.2% | 56.8% | 82.8% | — | 70.3% |
| Operating Margin | 58.4% | 58.4% | -29.6% | -5.0% | — | -72.5% |
| Net Margin | 54.9% | 54.9% | -27.8% | -0.9% | — | -71.4% |
| Balance Sheet | ||||||
| Current Ratio | 9.10 | 9.10 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $83.4M | $83.4M | $-24.7M | $20.4M | — | $-42.8M |
| Returns | ||||||
| ROE | 77.0% | 77.0% | -197.1% | -1.6% | — | — |
| Valuation | ||||||
| P/E | 3.47 | 3.47 | — | — | — | — |
| EV/EBITDA | 1.88 | 1.88 | — | — | — | — |
| P/B | 2.53 | 2.53 | 11.42 | 4.19 | 1.52 | — |
| Growth & Yield | ||||||
| Revenue Growth | 154.7% | 154.7% | 30.0% | — | — | — |
| EPS Growth | 476.9% | 476.9% | -2543.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-33.4%
EPS terminal req.
$0.29
Spread vs growth
510.3%
5Y implied EPS CAGR
-18.6%
EPS terminal req.
$0.35
Spread vs growth
495.5%
10Y implied EPS CAGR
-5.4%
EPS terminal req.
$0.56
Spread vs growth
482.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+629.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.26 → 0.98
Residual
+629.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.